ICD-10 Coding for Hormone Receptor-Positive Breast Cancer
The appropriate ICD-10 code for hormone receptor-positive breast cancer depends on the specific anatomical location and whether the cancer is in situ or invasive, but the primary code will be from the C50.x series for invasive breast cancer or D05.x for carcinoma in situ, with no specific ICD-10 code that directly designates hormone receptor status.
Understanding ICD-10 Coding Structure for Breast Cancer
ICD-10 does not have separate codes for hormone receptor status. The coding system focuses on anatomical location and histological type rather than molecular characteristics like estrogen receptor (ER) or progesterone receptor (PR) positivity 1, 2.
Primary Codes for Breast Cancer:
C50.x series: Malignant neoplasm of breast (invasive cancer)
- C50.0: Nipple and areola
- C50.1: Central portion of breast
- C50.2: Upper inner quadrant
- C50.3: Lower inner quadrant
- C50.4: Upper outer quadrant
- C50.5: Lower outer quadrant
- C50.6: Axillary tail
- C50.8: Overlapping sites
- C50.9: Breast, unspecified
D05.x series: Carcinoma in situ of breast
- D05.0: Lobular carcinoma in situ
- D05.1: Intraductal carcinoma in situ
- D05.9: Carcinoma in situ of breast, unspecified
Clinical Context and Documentation
While ICD-10 codes don't capture hormone receptor status, this information is clinically critical for treatment decisions. Over 70% of breast cancers are HR-positive 2, and this designation fundamentally determines whether patients receive endocrine therapy as their primary systemic treatment.
Important Coding Considerations:
For accurate medical records and billing, you should:
- Use the appropriate C50.x or D05.x code based on anatomical location
- Document hormone receptor status separately in the medical record
- Include ER and PR percentages from immunohistochemistry testing 3
- Note HER2 status as well, since treatment algorithms differ for HR+/HER2- versus HR+/HER2+ disease 2
Validation Studies Show High Accuracy
Research demonstrates that ICD-9-CM codes (the predecessor to ICD-10) for breast cancer have excellent sensitivity (96-100%) and specificity (90-98%) in identifying breast cancer cases in administrative databases 4. However, these codes identify the presence of breast cancer itself, not molecular subtypes.
Common Pitfalls to Avoid
Don't assume a single code captures all relevant information: ICD-10 codes identify the cancer location, but hormone receptor status must be documented separately in pathology reports and clinical notes 3.
Recognize that ER-low positive (1-10% staining) is heterogeneous: While technically coded the same way, these tumors may behave more like ER-negative cancers 5. Document the actual percentage.
For metastatic disease, use additional codes:
- C79.x series for secondary malignant neoplasms
- Document sites of metastasis (bone, liver, lung, etc.)
- This is critical since treatment algorithms differ significantly between early-stage and metastatic HR+ breast cancer 2
The hormone receptor status should be clearly documented in pathology reports using standardized immunohistochemistry criteria, with tumors showing ≥1% nuclear staining considered positive for ER or PR 3, 5.